BTIG analyst Robert Hazlett maintained a Buy rating on CTI BioPharma (CTIC – Research Report) yesterday and set a price target of $10.00. The company’s shares closed last Thursday at $4.67, close to its 52-week high of $5.25.
According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 5.9% and a 40.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and Nektar Therapeutics.
Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $8.12, a 61.1% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.
The company has a one-year high of $5.25 and a one-year low of $1.43. Currently, CTI BioPharma has an average volume of 4.82M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Read More on CTIC:
- Galaxy Digital Holdings (BRPHF) Gets a Buy Rating from BTIG
- Analysts Offer Insights on Technology Companies: Unity Software (U) and Sharecare (SHCR)
- Analysts Have Conflicting Sentiments on These Services Companies: TripAdvisor (TRIP) and Wingstop (WING)
- Nvidia (NVDA) Gets a Buy Rating from Wells Fargo
- Wells Fargo Thinks Five Below’s Stock is Going to Recover